Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunome (IMNM) Gains from Investment Securities (2023 - 2025)

Historic Gains from Investment Securities for Immunome (IMNM) over the last 3 years, with Q3 2025 value amounting to $5.4 million.

  • Immunome's Gains from Investment Securities rose 414.34% to $5.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.4 million, marking a year-over-year increase of 414.34%. This contributed to the annual value of $6.6 million for FY2024, which is 1707.29% down from last year.
  • Latest data reveals that Immunome reported Gains from Investment Securities of $5.4 million as of Q3 2025, which was up 414.34% from $902684.0 recorded in Q2 2025.
  • Over the past 5 years, Immunome's Gains from Investment Securities peaked at $8.5 million during Q2 2024, and registered a low of $348748.0 during Q1 2025.
  • For the 3-year period, Immunome's Gains from Investment Securities averaged around $3.7 million, with its median value being $3.0 million (2023).
  • Its Gains from Investment Securities has fluctuated over the past 5 years, first surged by 18103.27% in 2024, then crashed by 8942.75% in 2025.
  • Quarter analysis of 3 years shows Immunome's Gains from Investment Securities stood at $5.8 million in 2023, then crashed by 62.07% to $2.2 million in 2024, then soared by 144.85% to $5.4 million in 2025.
  • Its last three reported values are $5.4 million in Q3 2025, $902684.0 for Q2 2025, and $348748.0 during Q1 2025.